IL90374A0 - Cloned gene for expression of antibodies reacting with human ovarian cancer - Google Patents

Cloned gene for expression of antibodies reacting with human ovarian cancer

Info

Publication number
IL90374A0
IL90374A0 IL90374A IL9037489A IL90374A0 IL 90374 A0 IL90374 A0 IL 90374A0 IL 90374 A IL90374 A IL 90374A IL 9037489 A IL9037489 A IL 9037489A IL 90374 A0 IL90374 A0 IL 90374A0
Authority
IL
Israel
Prior art keywords
expression
ovarian cancer
human ovarian
cloned gene
antibodies reacting
Prior art date
Application number
IL90374A
Original Assignee
Us Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Commerce filed Critical Us Commerce
Publication of IL90374A0 publication Critical patent/IL90374A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL90374A 1988-05-23 1989-05-23 Cloned gene for expression of antibodies reacting with human ovarian cancer IL90374A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19770388A 1988-05-23 1988-05-23

Publications (1)

Publication Number Publication Date
IL90374A0 true IL90374A0 (en) 1989-12-15

Family

ID=22730416

Family Applications (1)

Application Number Title Priority Date Filing Date
IL90374A IL90374A0 (en) 1988-05-23 1989-05-23 Cloned gene for expression of antibodies reacting with human ovarian cancer

Country Status (3)

Country Link
AU (1) AU3693389A (en)
IL (1) IL90374A0 (en)
WO (1) WO1989011533A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU662311B2 (en) 1991-02-05 1995-08-31 Novartis Ag Recombinant antibodies specific for a growth factor receptor
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0247091B1 (en) * 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use

Also Published As

Publication number Publication date
AU3693389A (en) 1989-12-12
WO1989011533A1 (en) 1989-11-30

Similar Documents

Publication Publication Date Title
ZA902047B (en) External regulation of gene expression
YU91985A (en) Process for synthesis of biological active polypeptides of limfotoxine
GB8428321D0 (en) Production of antibodies
AU633629B2 (en) Intermediates in the synthesis of oxa- and azahomoyclostatine polypeptides
AU4733989A (en) Gene family of tumor-associated antigens
HK162795A (en) A novel family of high affinity modified antibodies for cancer treatment
ZA889659B (en) Synthesis of 1,2-dioxetanes and intermediates therefor
EP0344783A3 (en) Monochromator drift compensation
RO105652B1 (en) Reduction process of heterogeneity of monoclonal antibodies
AU7679687A (en) Monoclonal antibody specific for human colon fibroblast- derived t-pa
GB9005899D0 (en) Production of immobilised antibodies
IL90374A0 (en) Cloned gene for expression of antibodies reacting with human ovarian cancer
IL83291A0 (en) Monoclonal antibody against ovarian cancer cells(ovb-3)
IL86787A0 (en) Novel synthesis of 3-amino-2-methylbenzotrifluoride
GB8722020D0 (en) Human anti-rh(d)monoclonal antibodies
JPS5599193A (en) Artificially attached gene coding for protein synthesis and protein production
GB8727030D0 (en) Production of monoclonal antibodies
EP0253646A3 (en) Anti-human gastric cancer monoclonal antibody
GB8804802D0 (en) Preparation of monoclonal antibodies
GB2199828B (en) Synthesis of 2-(perfluoroalkyl)ethanethiols
EP0279669A3 (en) Monoclonal antibodies to human pancreatic cancer
GB2098992B (en) Corticoid synthesis via novel 17a-dihalovinyl-17b-ols and 21-sufenyl intermediates
GB8717863D0 (en) Determination of antibodies
JPS6418922A (en) Synthesis of arsine
ZA886752B (en) Tumor immunotherapy using anti-idiotypic antibodies